Pfizer raises revenue outlook after quarterly earnings top estimates

Pfizer Inc (NYSE:PFE, XETRA:PFE) bushed Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year gross guidance, arsenic maturation from launched and acquired products helped offset declines successful its COVID-19 portfolio.

The pharmaceutical institution reported adjusted net of $0.77 per stock for the quarter, supra the $0.68 expected by analysts. Revenue came successful astatine $15.03 billion, compared with the $14.40 cardinal statement estimate.

Pfizer reported quarterly gross of $15.0 billion, up 1% connected an operational ground from a twelvemonth earlier. Excluding Comirnaty and Paxlovid, gross accrued 5% operationally, portion gross from launched and acquired products roseate 18% operationally.

The institution reported a GAAP nonaccomplishment of $0.04 per share, reflecting $4.3 cardinal successful non-cash intangible plus impairments.

Pfizer raised its 2026 gross guidance by $500 cardinal astatine the midpoint to a scope of $60.5 cardinal to $62.5 billion. The institution reaffirmed its adjusted diluted net guidance of $2.80 to $3.00 per share, which includes an astir $0.10 interaction from its transaction with Innovent Biologics.

Pfizer besides announced further anticipated productivity savings of $2.5 cardinal associated with ongoing initiatives, with the savings expected to beryllium realized from 2027 done 2029.

"Pfizer had different beardown quarter, delivering connected our fiscal commitments and advancing our strategy," Pfizer CEO Albert Bourla said successful a statement.

"Our launched and acquired products performed well, our obesity programme is advancing with meaningful momentum and our oncology portfolio remains a root of strength."

Incoming Interim CFO Cecile Guegan added that the second-quarter results reflected "solid commercialized show globally" and continued absorption connected operational efficiency, highlighting the 18% operational gross maturation from launched and acquired products.

Shares of Pfizer were small changed astatine astir $25 post-earnings.